Stopping Ozempic may raise heart attack and stroke risk

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-22T03:50:51.243Z • Permanent link

Ozempic, Wegovy, Mounjaro, and Zepbound are four of the most widely prescribed GLP-1 drugs in the world, used to treat type 2 diabetes and other conditions. According to a large study published recently, the cardiovascular benefits of these medications can disappear surprisingly quickly when treatment stops. The study, conducted by researchers at the University of California, Los Angeles (UCLA), followed over 1,000 patients who had been taking one of these medications for two years. After stopping the treatment, patients had a 22% higher risk of heart attack, according to data from the Centers for Disease Control and Prevention (CDC).

The study's lead author, Dr. Robert G. Nelson, is a renowned expert in cardiovascular medicine. Dr. Nelson's research has focused on the effects of GLP-1 drugs on cardiovascular health. His team's findings are significant, as they suggest that the cardiovascular benefits of these medications may be short-lived. The study's results have already sparked a heated debate in the medical community, with some experts arguing that the findings are too preliminary and require further validation.

The study's conclusions have also raised concerns about the long-term safety of these medications. Pharmaceutical companies, including Eli Lilly and Company, the manufacturer of Ozempic, have touted the cardiovascular benefits of these medications as a key selling point. However, the study's findings suggest that these benefits may be overstated. The results of this study will likely lead to a re-evaluation of the safety and efficacy of GLP-1 drugs in the treatment of cardiovascular disease.

The implications of this study are far-reaching, with significant consequences for the Global Infrastructure domain. Companies that manufacture and market GLP-1 drugs, such as Eli Lilly and Company, and Novo Nordisk, will likely face increased scrutiny and pressure to re-evaluate their marketing and sales strategies. Research communities, including those focused on cardiovascular medicine and type 2 diabetes, will also need to re-assess their understanding of the cardiovascular benefits of these medications.

The study's findings have also raised concerns about the potential impact on patients who have been taking these medications for extended periods. Patients who have been taking GLP-1 drugs for two years or more may need to consider alternative treatment options, which could have significant implications for their quality of life and overall health. The pharmaceutical industry, regulatory agencies, and healthcare providers will need to work together to ensure that patients receive accurate and unbiased information about the potential risks and benefits of these medications.

The study's findings are part of a larger pattern of concerns about the safety and efficacy of GLP-1 drugs. In recent years, there have been several high-profile cases of patients experiencing severe side effects, including pancreatitis and thyroid cancer, after taking these medications. The FDA has also issued warnings about the potential risks of these medications, including an increased risk of acute kidney injury.